Why the study?
Does guideline-based management, including high-sensitivity troponin algorithms and risk stratification, improve outcomes in patients with NSTEMI?
Does guideline-based management, including high-sensitivity troponin algorithms and risk stratification, improve outcomes in patients with NSTEMI?
Answers are grounded in this paper and cite their sources.
This editorial highlights that adherence to guideline-directed management, appropriate use of high-sensitivity troponin algorithms, and risk stratification significantly improve long-term survival in patients with NSTEMI.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. The management of acute coronary syndromes (ACS) as recommended in the recent ESC Guidelines1–3 has made an impressive advancement in the last decades that is translated into a markedly better outcome,4,5 as convincingly documented in a FAST TRACK ‘Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from the SWEDEHEART registry 1995–2014’ by Karolina Szummer and colleagues from the Karolinska Institutet, in Stockholm, Sweden.6 The authors assessed the changes in short- and long-term outcomes in 205 693 cases with non-ST-elevation myocardial infarction (NSTEMI) of the SWEDEHEART registry. During 20 years, in-hospital invasive procedures increased from 1.9% to 73.2%, dual antiplatelet medication from 0% to 72.7%, statins from 13.3% to 85.6%, and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers from 36.8% to 75.5%. The 1-year mortality rate compared with a control population decreased from 5.53 to 3.03. If patients admitted in the first 2 years were modelled to receive the same treatments as the last 2 years the mortality and myocardial infarction rate would be reduced from 33% to 25%. After adjusting, the change of 1-year cardiovascular death and myocardial infarction corresponded to a linearly decreasing odds ratio trend of 0.930 per 2 years. Thus, during the last 20 years, long-term survival and risk of new cardiovascular events of NSTEMIs has markedly improved due to the widespread use of in-hospital coronary interventions and evidence-based medications. These remarkable findings are put into context in an Editorial by Elliott Marshall Antman from the Brigham and Women’s Hospital in Boston, Massachusetts, USA. 7 An important novelty in the management of ACS was the introduction of troponin as a diagnostic8,9 and prognostic marker.10 In the most recent NSTEMI guidelines, the 0/1-h algorhithm for high sensitivity troponin T (hs-TnT) has been introduced. The impact of this new recommendation is analysed in the article ‘Impact of age on the performance of the ESC 0/1-h algorithms for early diagnosis of myocardial infarction’ by Christian Mueller and the APACE, BACC, and TRAPID-AMI Investigators.11 They prospectively enrolled patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction in three large diagnostic registries. Patients were stratified into young (<55 years), middle aged (≥55 to <70 years), and old (≥70 years). Rule-out safety of the hs-cTnT 0/1-h algorithm was very high in all age strata with sensitivities between 100% and 99%. However, accuracy of rule-in decreased with age, with a specificity of 97% in young, 96% in middle-age, and 93% in the elderly (Figure 1). As a consequence, triage efficacy decreased with age. Similar results were found with hs-cTnI. Importantly, slightly higher cut-off levels optimized for older patients maintained high safety of rule-out and increased specificity of rule-in, but reduced overall efficacy for hs-cTnT, while maintaining efficacy for hs-cTnI. Thus, while the safety of the ESC 0/1-h algorithms remained very high, increasing age significantly reduced overall efficacy and the accuracy of rule-in. Slightly higher cut-off concentrations may be considered for older patients, particularly if using hs-cTnI, a conclusion that is put into context in an Editorial by Hugo A. Katus, the inventor of the troponin test,12 from the University Hospital Heidelberg in Germany.13 Diagnostic performance of the ESC high-sensitivity cardiac troponin T 0/1h-algorithm according to age in the main cohort (from Boeddinghaus J, Nestelberger T, Twerenbold R, Neumann JT, Lindahl B, Giannitsis E, Sörensen NA, Badertscher P, Jann JE, Wussler D, Puelacher C, Rubini Giménez M, Wildi K, Strebel I, Du Fay de Lavallaz J, Selman F, Sabti Z, Kozhuharov N, Potlukova E, Rentsch K, Miró Ò, Martin-Sanchez FJ, Morawiec B, Parenica J, Lohrmann J, Kloos W, Buser A, Geigy N, Keller DI, Osswald S, Reichlin T, Westermann D, Blankenberg S, Mueller C, for the APACE, BACC, and TRAPID-AMI Investigators. Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction. See pages 3780–3794). For risk assesssement, many scores have been introduced in primary prevention and in patients with ACS. In the latter population, the GRACE score with or without biomarkers is widely used.14–16 In their article entitled ‘Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction’, Owen John Bebb and colleagues from the University of Leeds in the UK investigated whether in 389 507 NSTEMI patients the GRACE risk score was associated with guideline-indicated diagnostics and treatments, and whether it persisted after hospital discharge.17 At 30 days, the use of optimal care was associated with improved survival among high-risk NSTEMI patients (Figure 2). After a median follow-up of 2.3 years, the association between the use of guideline-indicated treatments and improved survival only remained significant for high-risk NSTEMIs. Thus, optimal use of guideline-indicated care for NSTEMIs was associated with better survival with increasing GRACE score, but its use paradoxically decreased with increasing GRACE score, provocative findings that are further discussed in an Editorial by Marco Roffi from the Hospitaux Universitaire in Geneva Switzerland.18 Unadjusted landmark KaplanMeier survival curves and crude mortality rates by GRACE risk score category and receipt of optimal care vs. suboptimal care. This figure demonstrates the benchmarked crude mortality rates for the following time periods; 0–1 year, 1–2 years, 2–3 years, 3–8 years, across GRACE risk category by the receipt of optimal care. The percentages represent the crude mortality rates for each time period with the 95% confidence interval for each of the respective GRACE risk score categories. Population at risk at baseline; low GRACE risk category: 73 351, intermediate GRACE risk category: 59 201, high GRACE risk category: 52 005. Population at risk 38 years; low GRACE risk category: 70 069 intermediate GRACE risk category: 47 120, high GRACE risk category: 28 698 (from Hall M, Bebb OJ, Dondo TB, Yan AT, Goodman SG, Bueno H, Chew DP, Brieger D, Batin PD, Farkouh ME, Hemingway H, Timmis A, Fox KAA, Gale CP. Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. See pages 3798–3806). Although the presenting features and early sequelae of NSTEMI are well described,19,20 less is known about longer term risks and modes of death. In their article ‘Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials’ Robert P. Giugliano and colleagues from the TIMI Study Group, Brigham and Women’s Hospital in Boston, Massachusetts, USA addressed this in 66 252 patients with NSTEMI enrolled in 14 TIMI trials.21. Of patients followed for 372 days, 4.8% died. Of patients with known modes of death, 75% were related to a cardiovascular event, 3.0% to bleeding, and 22% to another event. The most common modes of cardiovascular death were sudden death and recurrent myocardial infarction. The proportion of cardiovascular deaths related to recurrent myocardial infarction was higher in the first 30 days than it was after 30 days following NSTEMI, whereas the proportion of sudden death was lower in the first 30 days than after 30 days. Thus, sudden death represents the largest proportion of cardiovascular deaths after 30 days among patients with NSTEMI. Further defining the epidemiology of sudden death and developing specific therapies and management approaches to such are critical to reducing late mortality, a conclusion that is further discussed in an Editorial by Lars Wallentin from the Uppsala Clinical Research Center in Sweden.22 This issue is complemented by two Discussion Forum contributions related to the manuscript ‘Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests’ by Filippo Crea and colleagues from the Università Cattolica del Santo Cuore in Rome, Italy.23 In their commentary ‘Type 2 myocardial infarction’, Christian Mueller and colleagues from the University Hospital in Basel, Switzerland highlight the need for using the appropriate definition of type 2 myocardial infarction.24 Niccoli et al. respond to Mueller’s comments in their contribution entitled ‘Reconsidering aetiologies of type 2 myocardial infarction: when a classification is a simplistic approach for a complex reality’.25 The editors of the European Heart Journal hope that this issue will be of interest to its readers.
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: